Business Wire

CHRYSO

Share
CHRYSO and CONDAT Technology Partnership in TBM Tunneling - Preview at AFTES 2021

CHRYSO, a leader in Construction chemicals, today announced a technology partnership with CONDAT. As CONDAT is a world expert in sealing, lubricants and ground treatment formulations for Tunnel Boring Machines (TBM), CHRYSO has joined forces with the company to develop a unique know-how in TBM tunneling applications combined with a scientific expertise of organo-mineral chemistry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210831005617/en/

The first technology issued from this collaboration is a cutting-edge patented backfill grout solution CHRYSO®TBM SGS (Smart Grout System) . The combined use of CHRYSO®TBM SGS 150 retarder and CHRYSO®TBM SGS 400 stabilizer ensure exceptional grout stability over several days. The grout stability and low viscosity allow for pumping over long distance and reduce the need for pipes flushing during machine stoppages, delivering unparalleled performance to meet the most demanding jobsites.

“We are bringing a high-performing environmentally-friendly backfill grout for tunnels and underground cities projects,” said Marc Plançon – Concrete Business Unit Deputy Director at CHRYSO.

CHRYSO®TBM SGS presents many advantages that significantly reduce tunneling construction site’s environmental footprint. The Stabilizer’s unique formulation allows to completely substitute bentonite, a non-renewable raw material commonly used in the backfill mix design. No more bentonite storing neither transport will also contribute to a better environmental management of the site.

“Furthermore, we offer a sustainable supply with our CHRYSO®TBM SGS 400 stabilizer which is based on renewable raw materials (bio-sourcing) and the possibility to use alternate cementitious materials such as GGBS (slag) for a reduced CO2 footprint. Our research plan is totally focused on providing sustainable solutions to our customers and lowering CO2 emissions,” added Marc Plançon.

“Combining support expertise and a worldwide network of laboratories and specialists of both CHRYSO and CONDAT ensures that our customers have access to a reinforced level of local service. This first collaboration on the Smart Grout System has given significant results and we are looking forward to further successful development of innovative solutions," said Thierry SANNA, Sales Director -Tunneling Division at CONDAT.

The two companies will showcase the new CHRYSO®TBM SGS solution at the upcoming AFTES 2021 event ”The underground, a space of innovation” in September in Paris.

> CHRYSO: booth n°133
> CONDAT: booths N°131 et 132

About CHRYSO: https://www.chryso.com/about-us/

About CONDAT: https://www.condat-lubricants.com/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

InterAx and Alveus Announce Strategic Research and Licensing Agreement to Develop Differentiated Therapeutic Candidate for Metabolic Disease15.1.2026 13:30:00 CET | Press release

InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic research collaboration and licensing agreement to develop a differentiated small molecule candidate for metabolic disease to deliver durable weight loss with superior tolerability. This partnership forms a joint research effort on a target and modality of established but untapped therapeutic interest by combining InterAx’s Deep Signal™ discovery platform – designed to optimize candidates toward superior signaling profiles – with Alveus’s deep R&D expertise and leadership in obesity, diabetes, and cardiometabolic disease. While financial terms remain undisclosed, the agreement includes an upfront payment and eligibility for future development, regulatory, and commercial milestones. “We are thrilled to join forces with Alveus to advance a highly differentiated therapeutic candidate designed to overcome the limitations of today’s obesity medications,” said Andrew Roberts, CEO of InterAx. “O

Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness15.1.2026 13:01:00 CET | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the closing of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The agreement is designed to accelerate global development and potential commercialization of Agenus’ botensilimab and balstilimab (BOT+BAL) immunotherapy combination program. The collaboration provides Agenus with strategic capital and committed, long-term biologics manufacturing capacity in the United States to support BOT+BAL clinical development, authorized early access pathways, and commercial supply preparation. As part of the collaboration, Agenus has granted Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka, with Agenus eligible to receive royalties on net sales in those territories. The collaboration, first announced on June 3, 2025, included the following key financial terms: Upfront Consideration: $75 million cash payment to Agenus for transfer of biologics manufac

WHOOP and Samuel Ross MBE Announce Multiyear, Global Creative Partnership, Introducing a New Era in Performance Fashion15.1.2026 13:00:00 CET | Press release

The WHOOP x SR_A collaboration ushers in a new frontier of performance accessories, apparel, and design-driven technology WHOOP, the human performance company, announces a landmark creative partnership with acclaimed designer Samuel Ross MBE, who joins as Global Creative Director, WHOOP x SR_A to lead a multiyear collaboration between the two brands titled PROJECT TERRAIN. The collaboration signals the ongoing evolution of WHOOP from a pioneering wearable technology company into a brand shaping not just the future of personal health but also its intersection with performance fashion and cultural design. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115643104/en/ WHOOP and Samuel Ross MBE Announce Multiyear, Global Creative Partnership, Introducing a New Era in Performance Fashion As the first performance design collaboration for WHOOP, the partnership represents a new chapter for the brand. Under Ross’ direction, PROJECT

TNG Digital and EPOS Launch EPOS360 and EPOS360 BlueTap in Malaysia to Help Local SMEs Grow with AI and Unique Payment Capabilities15.1.2026 11:23:00 CET | Press release

EPOS360, an industry-first all-in-one digital and payments solution, launches as a mini-programme within TNG eWallet, enabling Malaysian SMEs to easily access AI-powered growth tools to engage over 25 million TNG eWallet usersTNG Digital introduces EPOS360 BlueTap, Malaysia’s first tap-to-pay experience using TNG eWalletThrough EPOS, Ant International will make significant strides to empower SME digitalisation, leading the charge for its SME inclusion and growth strategy TNG Digital Sdn. Bhd. (“TNG Digital”), the operator of Malaysia’s leading digital financial services and lifestyle app, TNG eWallet, and EPOS, the all-in-one SME transformation platform of Ant International, have jointly announced the launch of EPOS360 in Malaysia, with a suite of AI-powered growth tools and unique payment capabilities to support the digitalisation of Malaysian businesses, particularly SMEs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260

UK CfD AR7 Results Signal New Realities for Offshore Wind Economics Ahead of AR8 — Aegir Insights15.1.2026 10:38:00 CET | Press release

The UK government yesterday published the results of the highly anticipated Contracts for Difference (CfD) Allocation Round 7 (AR7), highlighting both sustained appetite for UK offshore wind and the growing complexity of delivering competitive, bankable bids. The allocation round awarded a record 8.4 GW of offshore wind capacity across eight projects after the government increased the budget during the process. Almost all capacity (8.2 GW) was allocated to fixed-bottom offshore wind, enabling six large-scale projects to move forward and strengthening the UK’s deployment pipeline towards 2030. However, the outcome also revealed a large degree of project concentration, with partial or full ownership of five of the six awarded fixed-bottom projects held by a single developer. In a sector still recovering from cost and delivery risk, AR7 represents a positive outcome and signals an industry beginning to recalibrate under the right support framework. “The AR7 results provide important signa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye